全文获取类型
收费全文 | 371篇 |
免费 | 10篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 22篇 |
基础医学 | 20篇 |
口腔科学 | 4篇 |
临床医学 | 15篇 |
内科学 | 74篇 |
皮肤病学 | 4篇 |
神经病学 | 9篇 |
特种医学 | 7篇 |
外科学 | 109篇 |
预防医学 | 5篇 |
眼科学 | 1篇 |
药学 | 15篇 |
肿瘤学 | 97篇 |
出版年
2023年 | 2篇 |
2022年 | 5篇 |
2021年 | 11篇 |
2020年 | 3篇 |
2019年 | 4篇 |
2018年 | 6篇 |
2017年 | 2篇 |
2016年 | 8篇 |
2015年 | 7篇 |
2014年 | 12篇 |
2013年 | 17篇 |
2012年 | 37篇 |
2011年 | 28篇 |
2010年 | 17篇 |
2009年 | 12篇 |
2008年 | 30篇 |
2007年 | 26篇 |
2006年 | 37篇 |
2005年 | 41篇 |
2004年 | 18篇 |
2003年 | 27篇 |
2002年 | 17篇 |
2001年 | 4篇 |
2000年 | 2篇 |
1999年 | 2篇 |
1997年 | 1篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1993年 | 1篇 |
1991年 | 3篇 |
1990年 | 1篇 |
排序方式: 共有383条查询结果,搜索用时 62 毫秒
1.
N Xiros P Papacostas T Economopoulos G Samelis E Efstathiou E Kastritis H Kalofonos A Onyenadum D Skarlos A Bamias H Gogas D Bafaloukos E Samantas P Kosmidis 《Annals of oncology》2005,16(5):773-779
BACKGROUND: In the present phase II multicenter study, we assessed the efficacy and tolerability of the combination of gemcitabine and carboplatin in patients with advanced pancreatic cancer. PATIENTS AND METHODS: Patients with previously untreated, locally advanced or metastatic pancreatic cancer were treated with gemcitabine 800 mg/m(2) on days 1 and 8 and carboplatin at an AUC of 4 on day 8 of a 3-week cycle, for a total of six cycles. Primary end points were response rate and clinical benefit; secondary end points were, survival, time to progression (TTP) and toxicity. RESULTS: A total of 50 patients were enrolled in the study, 47 of whom were eligible for treatment. The median age was 63 years (range 34-76) and the median Karnofsky performance status (PS) was 80%. Patients received a median of six cycles (range 1-11). Among 35 patients evaluable for response, eight (17%) achieved partial response; 15 (32%) and 12 (25%) patients had stable and progressive disease, respectively. The median overall survival was 7.4 months; the median TTP was 4.4 months and the 1-year survival was 28%. The observed clinical benefit response was remarkable. After the second cycle of chemotherapy, 21 of 31 (68%) patients experienced pain improvement and reduced analgesic consumption. At the same time, 35% and 56% of our patients significantly improved their Karnofsky PS and weight, respectively. Overall, the treatment was well tolerated. The most common grade 3-4 toxicities were hematological, including 8% anemia, 6% neutropenia and 13% thrombocytopenia. CONCLUSIONS: The combination of gemcitabine plus carboplatin is a moderately active treatment for patients with locally advanced and metastatic pancreatic cancer. This regimen has an acceptable toxicity profile and provides a significant clinical benefit, and hence warrants further investigation. 相似文献
2.
H P Kalofonos G Aravantinos P Kosmidis P Papakostas T Economopoulos M Dimopoulos D Skarlos A Bamias D Pectasides S Chalkidou M Karina A Koutras E Samantas C Bacoyiannis G F Samelis G Basdanis F Kalfarentzos G Fountzilas 《Annals of oncology》2005,16(6):869-877
BACKGROUND: Irinotecan (IRI) and oxaliplatin (OXA) are effective in the treatment of colorectal cancer. Previously untreated patients with advanced colorectal carcinoma (CRC) were randomly assigned to receive IRI plus leucovorin (LV)/5-fluorouracil (5-FU), or OXA plus LV/5-FU in order to compare the response rates, time-to-tumor progression, overall survival rates, and toxicity profiles of these two agents. MATERIALS AND METHODS: From January 1999 to February 2002, 295 patients were randomized to receive either IRI/LV/5-FU or OXA/LV/5-FU. The treatment schedules consisted of weekly IRI 70 mg/m(2) or OXA 45 mg/m(2) plus LV 200 mg/m(2) followed immediately by intravenous bolus 5-FU 450 mg/m(2) for 6 weeks, followed by a 2-week rest period. Treatment was continued for up to four cycles or until disease progression, unacceptable toxicity or patient refusal. RESULTS: There were no significant differences between the study arms in the overall response rate (33% with IRI/LV/5-FU versus 32% with OXA/LV/5-FU based on responses demonstrated on a single evaluation; 23% with IRI/LV/5-FU versus 22.3% with OXA/LV/5-FU based on responses confirmed according to WHO criteria) median time to progression (8.9 versus 7.6 months), and median overall survival (17.6 versus 17.4 months). Toxicity profiles (grades 3 and 4) were similar in the IRI and OXA arms (diarrhea 12.3% and 9.8%, neutropenia 8.2% and 4.9%, and febrile neutropenia 1.4% and 1.4%, respectively), with the exception of grade 3 sensory neuropathy, which almost exclusively occurred in the OXA arm (0% versus 5.6%; P=0.003, Fisher's exact test). CONCLUSION: The IRI/LV/5-FU and OXA/LV/5-FU regimens demonstrated equally substantial efficacies and manageable toxicity profiles in the first-line treatment of patients with advanced CRC. However, IRI/LV/5-FU may be the preferable regimen to avoid significant neurotoxicity associated with OXA-LV/5-FU. 相似文献
3.
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. 总被引:23,自引:0,他引:23
Aristotle Bamias Efstathios Kastritis Christina Bamia Lia A Moulopoulos Ioannis Melakopoulos George Bozas Vassiliki Koutsoukou Dimitra Gika Athanasios Anagnostopoulos Christos Papadimitriou Evagelos Terpos Meletios A Dimopoulos 《Journal of clinical oncology》2005,23(34):8580-8587
PURPOSE: Osteonecrosis of the jaw (ONJ) has been associated recently with the use of pamidronate and zoledronic acid. We studied the incidence, characteristics, and risk factors for the development of ONJ among patients treated with bisphosphonates for bone metastases. PATIENTS AND METHODS: ONJ was assessed prospectively since July 2003. The first bisphosphonate treatment among patients with ONJ was administered in 1997. Two hundred fifty-two patients who received bisphosphonates since January 1997 were included in this analysis. RESULTS: Seventeen patients (6.7%) developed ONJ: 11 of 111 (9.9%) with multiple myeloma, two of 70 (2.9%) with breast cancer, three of 46 (6.5%) with prostate cancer, and one of 25 (4%) with other neoplasms (P = .289). The median number of treatment cycles and time of exposure to bisphosphonates were 35 infusions and 39.3 months for patients with ONJ compared with 15 infusions (P < .001) and 19 months (P = .001), respectively, for patients with no ONJ. The incidence of ONJ increased with time to exposure from 1.5% among patients treated for 4 to 12 months to 7.7% for treatment of 37 to 48 months. The cumulative hazard was significantly higher with zoledronic acid compared with pamidronate alone or pamidronate and zoledronic acid sequentially (P < .001). All but two patients with ONJ had a history of dental procedures within the last year or use of dentures. CONCLUSION: The use of bisphosphonates seems to be associated with the development of ONJ. Length of exposure seems to be the most important risk factor for this complication. The type of bisphosphonate may play a role and previous dental procedures may be a precipitating factor. 相似文献
4.
Sotirios G. Zarogiannis Aristotelis S. Filippidis Solana Fernandez Asta Jurkuvenaite Namasivayam Ambalavanan Andrei Stanishevsky Yogesh K. Vohra Sadis Matalon 《Respiratory physiology & neurobiology》2013,185(2):454-460
Titanium dioxide engineered nanoparticles (nano-TiO2) are widely used in the manufacturing of a number of products. Due to their size (<100 nm), when inhaled they may be deposited in the distal lung regions and damage Clara cells. We investigated the mechanisms by which short-term (1-h) incubation of human airway Clara-like (H441) cells to nano-TiO2 (6 nm in diameter) alters the ability of H441 cells to adhere to extracellular matrix. Our results show that 1 h post-incubation, there was a 3-fold increase of extracellular H2O2, increased intracellular oxidative stress as demonstrated by 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) oxidation, and a 5-fold increase of phosphor-ERK1/2 as measured by Western blotting. These changes were accompanied by a 25% decrease of H441 adherence to fibronectin (p < 0.05 compared to vehicle incubated H441 cells). Pretreatment with the ERK1/2 inhibitor U0126 for 3 h, partially prevented this effect. In conclusion, short-term exposure of H441 cells to nano-TiO2 appears to reduce adherence to fibronectin due to oxidative stress and activation of ERK1/2. 相似文献
5.
6.
Bamias A Basdanis G Xanthakis I Pavlidis N Fountzilas G 《Journal of gastrointestinal cancer》2005,36(1):29-38
Background. Although the TNM system is useful in predicting survival in resected colorectal cancer, heterogeneity within the same stages
regarding prognosis exists. We are presenting a pooled analysis of prognostic factors from two randomized studies of adjuvant
treatment conducted by the Hellenic Cooperative Oncology Group.
Patients and Methods. Patients with stage II or III colon (n=279) or rectal (n=220) cancer were included in this analysis. Following surgery, patients received: 5-fluorouracil/leucovorin (5-FU/LV) (n=135), 5-FU/LV and interferon Alfa-2a (IFNA-2a) (n=138), 5-FU/LV and pelvic chemoradiotherapy (n=106), and pelvic chemoradiotherapy alone (n=108).
Results. Median follow up was 92 mo. The number of involved lymph nodes (LNs), tumor differentiation, and the presence of regional
implants were independent prognostic factors for both OS and TTP, while nerve invasion was only significant for TTP. Patients
were stratified into three prognostic groups (low-risk: no LNs and grade 1/2; high-risk: >3 LNs and grade 3/4; intermediate-risk:
remaining patients) with distinct differences in 5-yr survival (84.7% vs 57.6% vs 32.4%) and 5-yr TTP (81.2% vs 54.5% vs 28.6%).
Conclusion. The combination of clinicopathological prognostic factors can be more informative than the traditional TNM staging system.
Such stratification may be necessary in randomized trials and could be useful in deciding the most appropriate adjuvant treatment
strategies. 相似文献
7.
Udo Nagele Karl-Dietrich Sievert Axel S. Merseburger Aristotelis G. Anastasiadis Arnulf Stenzl 《EAU Update Series》2005,3(3):129-137
Urinary diversion is an essential component of the surgical procedure after cystectomy. Replacement with an orthotopic ileal neobladder should be the first choice if external urethral sphincter sparing surgery is possible, offering good long-term function, quality of life and patient's acceptance with few complications.The possible use of a variety of alternative intestinal segments widen the horizon of the reconstructive surgeon, allowing him or her to be prepared for unusual cases.Contraindications for orthotopic neobladder reconstruction include tumour location, reduced renal, liver, intestinal function, intellectual ability and physical handicaps.It is therefore important to custom tailor the appropriate mode of diversion for individual patients with a variety of options available, including ureterocutaneous stomas, intestinal conduits and continent catheterizable reservoirs and orthotopic neobladders. All these techniques require detailed knowledge of the possible metabolic problems encountered by using gastrointestinal segments and how they react in contact with urine. Modern surgical techniques such as nerve sparing surgery have the ability to preserve postoperative continence with voluntarily micturition as well as sexual function. In addition, preliminary experimental data hold great promise that the “off shelf” bladder substitute may become a technique of choice in the future, avoiding common problems encountered using current technqiues. 相似文献
8.
Ioannis Papaconstantinou Evanthia Zampeli Dionysios Dellaportas Charalambos Giannopoulos Maria Sotiropoulou George Polymeneas Giorgos Bamias Spyros Michopoulos 《Clinical journal of gastroenterology》2014,7(2):132-135
Pouchitis occurs in up to one half of patients after restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). Cytomegalovirus (CMV) and Clostridium difficile are among the commonest secondary identifiable etiologies. A 17-year-old male with ulcerative colitis underwent IPAA due to refractory disease. Nine months later he experienced bloody diarrhea and fever. Laboratory testing and endoscopy confirmed pouch inflammation. Testing for C. difficile toxins A and B was positive. Histology revealed affluent inclusion bodies and immunohistochemistry detected reactivity against CMV protein. Treatment with metronidazole and vancomycin offered partial improvement, whereas the addition of gancyclovir led to a successful recovery. One month after completion of treatment symptoms recurred. Repeat testing precluded an identifiable infectious cause and the diagnosis of idiopathic chronic pouchitis was established. The patient is currently on maintenance treatment with the probiotic compound VSL#3. 相似文献
9.
10.
Papayannis A Banerjee S Brilakis ES 《Catheterization and cardiovascular interventions》2012,80(2):E30-E36
We describe treatment of six chronic total occlusions due to in-stent restenosis with the CrossBoss catheter (BridgePoint Medical, Minneapolis, Minnesota). The CrossBoss catheter allowed successful CTO crossing in 5 of 6 lesions (83%): in 50% the catheter entered the distal true lumen, whereas in 33% a wire was required for distal true lumen crossing. No complications were observed. Use of the CrossBoss catheter can facilitate treatment of coronary chronic total occlusions due to in-stent restenosis. 相似文献